News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PharmStar Pharmaceuticals, Inc. Announces New Product Line Extension


6/29/2011 8:55:24 AM

WILSON, NC--(Marketwire - June 29, 2011) -

PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company") today announced that it has added an additional line extension product to Aquaprin™ called "AQUAPRIN CHILDREN & TEENAGERS."

Yesterday, the Company received confirmation that the label for this new product meets FDA and FTC consumer warning label requirements for all products containing aspirin. The product contains 81 mg of aspirin and delivers approximately 65 mg of heart-healthy potassium. Like regular Aquaprin, the product solubilizes into a clear liquid instantly on contact with water, juices, milk, or any other water-containing liquid. The product is tasteless and has more than twice the power of aspirin tablets, powders, or oral suspensions. The product is packaged in a small 1-inch x 2-inch foil packet.

PharmStar plans to introduce a total of three products upon initial rollout:

  • AQUAPRIN ORIGINAL
  • AQUAPRIN DAILY REGIMEN
  • AND AQUAPRIN CHILDRENS AND TEENAGERS

INSTAPRIN, for emergency administration, will follow on a few months later.

PharmStar CEO, Howard Phykitt, stated, "We estimate the size of the 81 mg market to be equal to or greater than the entire adult aspirin market. Consequently, the addition of 'AQUAPRIN CHILDREN'S AND TEENAGERS' to our product line opens the door to potentially double the size of the Company's overall target market."

About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Wilson, NC. For more information, visit www.pharmstarinc.com.

Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.


Contact:
PharmStar, Inc.
919-794-7000
info@pharmstarinc.com
www.pharmstarinc.com
Investor Contact: investors@pharmstarinc.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES